FR2984129B1 - Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu - Google Patents

Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu

Info

Publication number
FR2984129B1
FR2984129B1 FR1161621A FR1161621A FR2984129B1 FR 2984129 B1 FR2984129 B1 FR 2984129B1 FR 1161621 A FR1161621 A FR 1161621A FR 1161621 A FR1161621 A FR 1161621A FR 2984129 B1 FR2984129 B1 FR 2984129B1
Authority
FR
France
Prior art keywords
scalp
prevention
treatment
polypeptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1161621A
Other languages
English (en)
Other versions
FR2984129A1 (fr
Inventor
Audrey Gueniche
Isabelle Castiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Priority to FR1161621A priority Critical patent/FR2984129B1/fr
Priority to PCT/IB2012/057242 priority patent/WO2013088371A2/fr
Publication of FR2984129A1 publication Critical patent/FR2984129A1/fr
Application granted granted Critical
Publication of FR2984129B1 publication Critical patent/FR2984129B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase

Abstract

La présente invention concerne l'utilisation cosmétique d'une quantité efficace d'au moins un actif consistant en un polypeptide ayant au moins 80 % d'identité en acides aminés avec une métalloprotéinase MMP-12 de séquence choisie parmi SEQ ID NO: 1, SEQ ID NO: 2 et SEQ ID NO: 3, ou un fragment C-terminal dudit polypeptide, pour prévenir et/ou traiter les états pelliculaires du cuir chevelu, ledit polypeptide ou ledit fragment comprenant la séquence KDXK, dans laquelle X représente l'acide aspartique ou l'acide glutamique
FR1161621A 2011-12-14 2011-12-14 Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu Active FR2984129B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1161621A FR2984129B1 (fr) 2011-12-14 2011-12-14 Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu
PCT/IB2012/057242 WO2013088371A2 (fr) 2011-12-14 2012-12-12 Utilisation de la protéine mmp-12 dans la prévention et/ou le traitement d'états pélliculaires du cuir chevelu

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1161621A FR2984129B1 (fr) 2011-12-14 2011-12-14 Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu

Publications (2)

Publication Number Publication Date
FR2984129A1 FR2984129A1 (fr) 2013-06-21
FR2984129B1 true FR2984129B1 (fr) 2014-01-10

Family

ID=45926673

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1161621A Active FR2984129B1 (fr) 2011-12-14 2011-12-14 Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu

Country Status (2)

Country Link
FR (1) FR2984129B1 (fr)
WO (1) WO2013088371A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018237218A1 (fr) 2017-06-23 2018-12-27 The Procter & Gamble Company Composition et procédé permettant d'améliorer l'aspect de la peau
US11622963B2 (en) 2018-07-03 2023-04-11 The Procter & Gamble Company Method of treating a skin condition
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
CN115843238A (zh) 2020-06-01 2023-03-24 宝洁公司 改善维生素b3化合物渗透到皮肤中的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235577A1 (en) * 2002-04-08 2003-12-25 Shapiro Steven D. Methods and compositions for preventing and treating microbial infections
DE10324567A1 (de) 2003-05-30 2004-12-23 Symrise Gmbh & Co. Kg Verwendung von Diphenylmethan-Derivaten als antimikrobielle Wirkstoffe
TWI395593B (zh) * 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制

Also Published As

Publication number Publication date
WO2013088371A2 (fr) 2013-06-20
WO2013088371A3 (fr) 2013-12-27
FR2984129A1 (fr) 2013-06-21

Similar Documents

Publication Publication Date Title
EA201000441A1 (ru) Водные офтальмологические препараты
EA200971053A1 (ru) Способы лечения кожных язв
CO6230997A2 (es) Proteinas de union a antigeno contra proproteina convertasa subtilisina/kexina tipo 9 (pcsk9)
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
MA41759A (fr) Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide
FR2984129B1 (fr) Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu
MA35507B1 (fr) Protéines à double fonction pour le traitement de troubles du métabolisme
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
BR112012019924A2 (pt) polipeptídeos de ligação de agonista de dr5.
EA201200515A1 (ru) Полипептиды и их применение
RU2011138183A (ru) Висфатиновые терапевтические средства для лечения акне и других состояний
EA202190888A1 (ru) Пептид для применения в косметике
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
EA201300062A1 (ru) Фармацевтическая композиция, предназначенная для лечения заболеваний центральной и периферической нервной системы сосудистого, травматического, токсического, гипоксического и аутоиммунного генеза
AR073810A1 (es) Polipeptidos que tienen actividad antimicrobiana
MX2021006253A (es) Terapias génicas para enfermedad neurodegenerativa.
FR2942720B1 (fr) Utilisation cosmetique d'hesperidine.
EA202090802A1 (ru) Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью
MA49396B1 (fr) Traitement de la migraine avec acétyl-leucine
TR201901846T4 (tr) Aşı terapisi.
ATE541566T1 (de) Zusammensetzungen zur behandlung von erkrankungen der augenoberfläche
FR2938429B1 (fr) Utilisation cosmetique de microorganisme(s) pour le traitement des desordres du cuir chevelu
FR2999386B1 (fr) Composition pour stimuler la vitalite des plantes

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13